Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations. The overall survival of patients with advanced NSCLC has improved dramatically with the development of comprehensive gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang-Si, Jie, Guang-Ling, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475243/
https://www.ncbi.nlm.nih.gov/pubmed/37667782
http://dx.doi.org/10.1177/17588359231193726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475243/
https://www.ncbi.nlm.nih.gov/pubmed/37667782
http://dx.doi.org/10.1177/17588359231193726

Ejemplares similares